Amgen (AMGN) posted second quarter revenue of $8.4 billion, coming in slightly above the estimated $8.34 billion. However, the pharmaceutical company missed on adjusted earnings expectations by just a hair, coming in at $4.97 per share instead of $4.98.

Yahoo Finance Senior Reporter Anjalee Khemlani digs into the earnings report and how its obesity drug MariTide could provide an earnings boost down the line if approved.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime.

This post was written by Melanie Riehl